Haemorrhagic intracranial complications associated with vaccine-induced thrombocytopenia or central venous thrombosis after COVID-19 vaccination: postulated underlying mechanisms with literature and case review
Abstract
Despite the unequivocal medical and social advantages of introducing vaccines against the novel coronavirus SARS-CoV-2, there were also some concerns regarding possible post-vaccination adverse events. Most of these are mild. But in rare cases, severe neurological symptoms including ischaemic stroke, intracranial haemorrhage (ICH), cerebral venous and sinus thrombosis (CVT), and thrombosis with thrombocytopenia (TTS) have been observed. Literature data suggests that thrombosis with thrombocytopenia was the major underlying cause of the ICH; dural venous sinuses/cerebral veins were indicated as the primarily affected sites of thrombosis. Our review confirms the previously documented suspicion that CVT and TTS are most likely to occur following vector-type, rather than mRNA, vaccine administration. The postulated mechanism of TTS is similar to heparin-induced thrombocytopenia (HIT) both clinically and serologically. Although ICH and VITT are very rare side effects of the COVID-19 vaccine, for patients with risk factors for thrombosis (e.g. pregnancy), physicians should carefully consider the benefit/risk ratio of vaccination.
Keywords: SARS-CoV-2COVID-19vaccineshaemorrhagic strokesinus thrombosis
References
- WHO Coronavirus (COVID-19) Dashboard n.d. https://covid19.who.int (23.04.2022).
- Baden LR, El Sahly HM, Essink B, et al. COVE Study Group. Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine. N Engl J Med. 2021; 384(5): 403–416.
- Polack FP, Thomas SJ, Kitchin N, et al. C4591001 Clinical Trial Group. Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine. N Engl J Med. 2020; 383(27): 2603–2615.
- Voysey M, Costa Clemens SA, Madhi SA, et al. Oxford COVID Vaccine Trial Group. Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials. Lancet. 2021; 397(10277): 881–891.
- Meo SA, Bukhari IA, Akram J, et al. COVID-19 vaccines: comparison of biological, pharmacological characteristics and adverse effects of Pfizer/BioNTech and Moderna Vaccines. Eur Rev Med Pharmacol Sci. 2021; 25(3): 1663–1669.
- Dias L, Soares-Dos-Reis R, Meira J, et al. Cerebral Venous Thrombosis after BNT162b2 mRNA SARS-CoV-2 vaccine. J Stroke Cerebrovasc Dis. 2021; 30(8): 105906.
- Takeyama R, Fukuda K, Kouzaki Y, et al. Intracerebral hemorrhage due to vasculitis following COVID-19 vaccination: a case report. Acta Neurochir (Wien). 2022; 164(2): 543–547.
- Schulz JB, Berlit P, Diener HC, et al. German Society of Neurology SARS-CoV-2 Vaccination Study Group. COVID-19 Vaccine-Associated Cerebral Venous Thrombosis in Germany. Ann Neurol. 2021; 90(4): 627–639.
- Research C for BE and. Coronavirus (COVID-19) | CBER-Regulated Biologics. FDA 2024. h. https://www.fda.gov/vaccines-blood-biologics/industry-biologics/coronavirus-covid-19-cber-regulated-biologics (9.05.2024).
- Vaxzevria (previously COVID-19 Vaccine AstraZeneca) | European Medicines Agency n.d. https://www.ema.europa.eu/en/medicines/human/EPAR/vaxzevria-previously-covid-19-vaccine-astrazeneca (9.05.2024).
- EMA. COVID-19 vaccines. European Medicines Agency 2021. https://www.ema.europa.eu/en/human-regulatory/overview/public-health-threats/coronavirus-disease-covid-19/treatments-vaccines/covid-19-vaccines (14.06.2022).
- Muhar BK, Nehira J, Malhotra A, et al. The Race for COVID-19 Vaccines: The Various Types and Their Strengths and Weaknesses. J Pharm Pract. 2023; 36(4): 953–966.
- Chi WY, Li YD, Huang HC, et al. COVID-19 vaccine update: vaccine effectiveness, SARS-CoV-2 variants, boosters, adverse effects, and immune correlates of protection. J Biomed Sci. 2022; 29(1): 82.
- Sahin U, Karikó K, Türeci Ö. mRNA-based therapeutics--developing a new class of drugs. Nat Rev Drug Discov. 2014; 13(10): 759–780.
- Recombinant Nanoparticle Vaccine Technology | Novavax n.d. https://www.novavax.com/science-technology/recombinant-protein-based-nanoparticle-vaccine-technology (14.06.2022).
- Arepally GM, Ortel TL. Vaccine-induced immune thrombotic thrombocytopenia: what we know and do not know. Blood. 2021; 138(4): 293–298.
- Wang Z, Yang Y, Liang X, et al. COVID-19 Associated Ischemic Stroke and Hemorrhagic Stroke: Incidence, Potential Pathological Mechanism, and Management. Front Neurol. 2020; 11: 571996.
- Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020; 395(10223): 497–506.
- Romero-Sánchez CM, Díaz-Maroto I, Fernández-Díaz E, et al. Neurologic manifestations in hospitalized patients with COVID-19: The ALBACOVID registry. Neurology. 2020; 95(8): e1060–e1070.
- Li Z, Liu T, Yang N, et al. Neurological manifestations of patients with COVID-19: potential routes of SARS-CoV-2 neuroinvasion from the periphery to the brain. Front Med. 2020; 14(5): 533–541.
- Wiese OJ, Allwood BW, Zemlin AE. COVID-19 and the renin-angiotensin system (RAS): A spark that sets the forest alight? Med Hypotheses. 2020; 144: 110231.
- Drelich-Zbroja A, Cheda M, Kuczyńska M, et al. Parkinson's Disease in Light of the COVID-19 Pandemic. Brain Sci. 2022; 12(2).
- Choi JKi, Kim S, Kim SR, et al. Intracerebral Hemorrhage due to Thrombosis with Thrombocytopenia Syndrome after Vaccination against COVID-19: the First Fatal Case in Korea. J Korean Med Sci. 2021; 36(31): e223.
- Syed K, Chaudhary H, Donato A. Central Venous Sinus Thrombosis with Subarachnoid Hemorrhage Following an mRNA COVID-19 Vaccination: Are These Reports Merely Co-Incidental? Am J Case Rep. 2021; 22: e933397.
- Purkayastha P, Mckechnie C, Kalkur P, et al. Rare case of COVID-19 vaccine-associated intracranial haemorrhage with venous sinus thrombosis. BMJ Case Rep. 2021; 14(9).
- Pavord S, Scully M, Hunt BJ, et al. Clinical Features of Vaccine-Induced Immune Thrombocytopenia and Thrombosis. N Engl J Med. 2021; 385(18): 1680–1689.
- Lin YH, Huang H, Hwang WZ. Moyamoya disease with Sjogren disease and autoimmune thyroiditis presenting with left intracranial hemorrhage after messenger RNA-1273 vaccination: A case report. Medicine (Baltimore). 2022; 101(6): e28756.
- Scott RM, Smith ER. Moyamoya disease and moyamoya syndrome. N Engl J Med. 2009; 360(12): 1226–1237.
- Mendes-de-Almeida DP, Martins-Gonçalves R, Morato-Santos R, et al. Intracerebral hemorrhage associated with vaccine-induced thrombotic thrombocytopenia following ChAdOx1 nCOVID-19 vaccine in a pregnant woman. Haematologica. 2021; 106(11): 3025–3028.
- Baba Y, Sakai H, Kabasawa N, et al. Successful Treatment of Immune Thrombocytopenic Purpura with Intracranial Hemorrhaging and Duodenal Bleeding Following SARS-CoV-2 Vaccination. Intern Med. 2022; 61(12): 1891–1895.
- Bjørnstad-Tuveng TH, Rudjord A, Anker P. Fatal cerebral haemorrhage after COVID-19 vaccine. Tidsskr Nor Laegeforen. 2021; 141.
- Franchini M, Liumbruno GM, Pezzo M. COVID-19 vaccine-associated immune thrombosis and thrombocytopenia (VITT): Diagnostic and therapeutic recommendations for a new syndrome. Eur J Haematol. 2021; 107(2): 173–180.
- Moores G, Warkentin TE, Farooqi MAM, et al. Spontaneous Heparin-Induced Thrombocytopenia Presenting as Cerebral Venous Sinus Thrombosis. Neurol Clin Pract. 2021; 11(6): e929–e931.
- Greinacher A, Selleng K, Warkentin TE. Autoimmune heparin-induced thrombocytopenia. J Thromb Haemost. 2017; 15(11): 2099–2114.
- Greinacher A, Thiele T, Warkentin TE, et al. Thrombotic Thrombocytopenia after ChAdOx1 nCov-19 Vaccination. N Engl J Med. 2021; 384(22): 2092–2101.
- Medić MG, Tomac G, Rimac V, et al. Fatal intracranial hemorrhage in patient with thrombocytopenia and positive HIT antibodies after vaccination with ChAdOx1 nCoV-19 - VITT without thrombosis? Thromb Res. 2022; 215: 55–57.
- Piñar-Gutiérrez A, Remón-Ruiz P, Soto-Moreno A. Case report: Pituitary apoplexy after COVID-19 vaccination. Med Clin (Barc). 2022; 158(10): 498–499.
- Athyros VG, Doumas M. A Possible Case of Hypertensive Crisis With Intracranial Haemorrhage After an mRNA Anti-COVID-19 Vaccine. Angiology. 2022; 73(1): 87.
- Carli G, Nichele I, Ruggeri M, et al. Deep vein thrombosis (DVT) occurring shortly after the second dose of mRNA SARS-CoV-2 vaccine. Intern Emerg Med. 2021; 16(3): 803–804.
- Ihle-Hansen H, Bøås H, Tapia G, et al. Stroke After SARS-CoV-2 mRNA Vaccine: A Nationwide Registry Study. Stroke. 2023; 54(5): e190–e193.
- Atzenhoffer M, Auffret M, Pegat A, et al. Guillain-Barré Syndrome Associated with COVID-19 Vaccines: A Perspective From Spontaneous Report Data. Clin Drug Investig. 2022; 42(7): 581–592.
- Sprow G, Afarideh M, Dan J, et al. Autoimmune Skin Disease Exacerbations Following COVID-19 Vaccination. Front Immunol. 2022; 13: 899526.
- Idiculla PS, Gurala D, Palanisamy M, et al. Cerebral Venous Thrombosis: A Comprehensive Review. Eur Neurol. 2020; 83(4): 369–379.
- Jolink WMT, Wiegertjes K, Rinkel GJE, et al. Location-specific risk factors for intracerebral hemorrhage: Systematic review and meta-analysis. Neurology. 2020; 95(13): e1807–e1818.
- Litwin M, Kułaga Z. Obesity, metabolic syndrome, and primary hypertension. Pediatr Nephrol. 2021; 36(4): 825–837.
- Piché ME, Tchernof A, Després JP. Obesity Phenotypes, Diabetes, and Cardiovascular Diseases. Circ Res. 2020; 126(11): 1477–1500.
- Scully M, Singh D, Lown R, et al. Pathologic Antibodies to Platelet Factor 4 after ChAdOx1 nCoV-19 Vaccination. N Engl J Med. 2021; 384(23): 2202–2211.
![](https://journals.viamedica.pl/plugins/generic/popups/images/icons/close.png)